BioCentury | Jan 5, 2019
Finance

Ready to launch

...data 1H19 Cassiopea S.p.A. (SIX:SKIN) Winlevi clascoterone Acne Submit NDA 1H19 Cel-Sci Corp. (NYSE-A:CVM) / Orient Europharma Co. Ltd....
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...Top-line Ph III data; submit NDA Early 2017; 1H17 Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) / Orient Europharma Co. Ltd....
BioCentury | Jul 25, 2016
Company News

Aeterna Zentaris, Orient Europharma deal

...terms, and Orient did not respond to inquiries. Aeterna Zentaris Inc. (TSX:AEZ;NASDAQ:AEZS), Quebec City, Quebec Orient Europharma Co. Ltd....
BioCentury | Jun 9, 2014
Company News

Debiopharm, Orient EuroPharma Co. Ltd. deal

...Debiopharm granted Orient EuroPharma exclusive commercialization rights to Pamorelin LA in Singapore and undisclosed countries in Southeast...
...to Pamorelin LA in Singapore and undisclosed countries in Southeast Asia. The partners also said Orient EuroPharma...
...declined to disclose details, and Orient could not be reached. Debiopharm Group , Lausanne, Switzerland Orient EuroPharma Co. Ltd....
BioCentury | Sep 30, 2013
Company News

NanoCarrier, Orient Europharma deal

...to disclose financial terms (see BioCentury, Nov. 12, 2012). NanoCarrier Co. Ltd. (Tokyo:4571), Chiba, Japan Orient Europharma Co. Ltd....
BioCentury | Nov 12, 2012
Company News

NanoCarrier, Orient Europharma deal

...amend the deal last month (see BioCentury, Oct. 22). NanoCarrier Co. Ltd. (Tokyo:4571), Chiba, Japan Orient Europharma Co. Ltd....
BioCentury | Oct 22, 2012
Company News

NanoCarrier, Orient Europharma deal

...testing to treat pancreatic cancer (see BioCentury, Oct. 15). NanoCarrier Co. Ltd. (Tokyo:4571), Chiba, Japan Orient Europharma Co. Ltd....
BioCentury | Oct 15, 2012
Clinical News

Nanoplatin: Phase I/II data

...to complete the trial by the end of its fiscal year ending March 31, 2013. Orient Europharma...
...mainland China and India, under a September 2008 deal. NanoCarrier Co. Ltd. (Tokyo:4571), Chiba, Japan Orient Europharma Co. Ltd....
BioCentury | Jun 18, 2012
Clinical News

Nanoplatin: Completed Phase I/II enrollment

...The Phase I portion determined that 90 mg/m 2 was the recommended dose of Nanoplatin. Orient Europharma...
...mainland China and India, under a September 2008 deal. NanoCarrier Co. Ltd. (Tokyo:4571), Chiba, Japan Orient Europharma Co. Ltd....
BioCentury | May 31, 2010
Company News

AndroScience, Orient deal

...European pharma companies to license ASC-J9 in global markets. AndroScience Corp. , San Diego, Calif. Orient Europharma Co. Ltd....
Items per page:
1 - 10 of 18
BioCentury | Jan 5, 2019
Finance

Ready to launch

...data 1H19 Cassiopea S.p.A. (SIX:SKIN) Winlevi clascoterone Acne Submit NDA 1H19 Cel-Sci Corp. (NYSE-A:CVM) / Orient Europharma Co. Ltd....
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

...Top-line Ph III data; submit NDA Early 2017; 1H17 Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) / Orient Europharma Co. Ltd....
BioCentury | Jul 25, 2016
Company News

Aeterna Zentaris, Orient Europharma deal

...terms, and Orient did not respond to inquiries. Aeterna Zentaris Inc. (TSX:AEZ;NASDAQ:AEZS), Quebec City, Quebec Orient Europharma Co. Ltd....
BioCentury | Jun 9, 2014
Company News

Debiopharm, Orient EuroPharma Co. Ltd. deal

...Debiopharm granted Orient EuroPharma exclusive commercialization rights to Pamorelin LA in Singapore and undisclosed countries in Southeast...
...to Pamorelin LA in Singapore and undisclosed countries in Southeast Asia. The partners also said Orient EuroPharma...
...declined to disclose details, and Orient could not be reached. Debiopharm Group , Lausanne, Switzerland Orient EuroPharma Co. Ltd....
BioCentury | Sep 30, 2013
Company News

NanoCarrier, Orient Europharma deal

...to disclose financial terms (see BioCentury, Nov. 12, 2012). NanoCarrier Co. Ltd. (Tokyo:4571), Chiba, Japan Orient Europharma Co. Ltd....
BioCentury | Nov 12, 2012
Company News

NanoCarrier, Orient Europharma deal

...amend the deal last month (see BioCentury, Oct. 22). NanoCarrier Co. Ltd. (Tokyo:4571), Chiba, Japan Orient Europharma Co. Ltd....
BioCentury | Oct 22, 2012
Company News

NanoCarrier, Orient Europharma deal

...testing to treat pancreatic cancer (see BioCentury, Oct. 15). NanoCarrier Co. Ltd. (Tokyo:4571), Chiba, Japan Orient Europharma Co. Ltd....
BioCentury | Oct 15, 2012
Clinical News

Nanoplatin: Phase I/II data

...to complete the trial by the end of its fiscal year ending March 31, 2013. Orient Europharma...
...mainland China and India, under a September 2008 deal. NanoCarrier Co. Ltd. (Tokyo:4571), Chiba, Japan Orient Europharma Co. Ltd....
BioCentury | Jun 18, 2012
Clinical News

Nanoplatin: Completed Phase I/II enrollment

...The Phase I portion determined that 90 mg/m 2 was the recommended dose of Nanoplatin. Orient Europharma...
...mainland China and India, under a September 2008 deal. NanoCarrier Co. Ltd. (Tokyo:4571), Chiba, Japan Orient Europharma Co. Ltd....
BioCentury | May 31, 2010
Company News

AndroScience, Orient deal

...European pharma companies to license ASC-J9 in global markets. AndroScience Corp. , San Diego, Calif. Orient Europharma Co. Ltd....
Items per page:
1 - 10 of 18